XML 44 R31.htm IDEA: XBRL DOCUMENT v3.8.0.1
Organization and Summary of Significant Accounting Policies - Narrative (Details)
$ in Thousands
 3 Months Ended 23 Months Ended
Mar. 30, 2018
USD ($)
segment
product
Dec. 31, 2017
USD ($)
Dec. 29, 2017
USD ($)
Dec. 30, 2017
USD ($)
Feb. 29, 2016
USD ($)
Organization And Summary Of Significant Policies [Line Items]          
Number of products that entered in the commercial marketplace | product 3        
Number of business segments | segment 1        
Reduction to accumulated deficit $ (1,454,810)   $ (1,829,172) [1] $ (1,570,667)  
Prompt payment discount rate 2.00%        
Percent of total available discounts expected to be earned 100.00%        
Products Derived from Cabozantinib          
Organization And Summary Of Significant Policies [Line Items]          
Number of products that entered in the commercial marketplace | product 2        
Collaborative Arrangement with Ipsen          
Organization And Summary Of Significant Policies [Line Items]          
Milestone payments earned     $ 125,000    
Additional milestone achievement         $ 199,000
Collaborative Arrangement with Ipsen | HCC Filing          
Organization And Summary Of Significant Policies [Line Items]          
Milestone payments earned   $ 10,000      
Collaborative Arrangement with Ipsen | EMA Approval          
Organization And Summary Of Significant Policies [Line Items]          
Milestone revenue recognized $ 45,800        
Additional milestone achievement 50,000        
ASU 2014-09 | Adjustments Due to the Adoption of Topic 606          
Organization And Summary Of Significant Policies [Line Items]          
Reduction to accumulated deficit $ 289,012     $ 258,505  
[1] The Condensed Consolidated Balance Sheet as of December 31, 2017 has been derived from the audited financial statements as of that date.